Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 7
Submit an article Journal homepage
56
Views
8
CrossRef citations to date
0
Altmetric
Review

Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?

Konstantinos Tziomalos University College London, (University of London), Royal Free University College Medical School, Royal Free Hospital, Department of Clinical Biochemistry (Vascular Prevention Clinic), Pond Street, London NW3 2QG, UK +44 20 7830 2258; +44 20 7830 2235; [email protected]; Aristotle University, Hippokration Hospital, Second Propedeutic Department of Internal Medicine, Thessaloniki, Greece
, MD,
Vasilios G Athyros Aristotle University, Hippokration Hospital, Second Propedeutic Department of Internal Medicine, Thessaloniki, Greece
, MD,
Asterios Karagiannis Aristotle University, Hippokration Hospital, Second Propedeutic Department of Internal Medicine, Thessaloniki, Greece
, MD &
Dimitri P Mikhailidis University College London, (University of London), Royal Free University College Medical School, Royal Free Hospital, Department of Clinical Biochemistry (Vascular Prevention Clinic), Pond Street, London NW3 2QG, UK +44 20 7830 2258; +44 20 7830 2235; [email protected]
, MD FFPM FRCP FRCPath
Pages 809-820 | Published online: 13 Jun 2008

Bibliography

  • Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231-43
  • Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-4
  • Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142-7
  • Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-11
  • Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006;114:e84-231
  • Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007;28:230-68
  • Goodney PP, O'Connor GT, Wennberg DE, Birkmeyer JD. Do hospitals with low mortality rates in coronary artery bypass also perform well in valve replacement? Ann Thorac Surg 2003;76:1131-6
  • Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 2005;111:3290-5
  • Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997;95:2262-70
  • Rosenhek R, Klaar U, Schemper M, et al. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J 2004;25:199-205
  • Aronow WS, Ahn C, Shirani J, Kronzon I. Comparison of frequency of new coronary events in older persons with mild, moderate, and severe valvular aortic stenosis with those without aortic stenosis. Am J Cardiol 1998;81:647-9
  • Davies MJ, Treasure T, Parker DJ. Demographic characteristics of patients undergoing aortic valve replacement for stenosis: relation to valve morphology. Heart 1996;75:174-8
  • Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005;111:3316-26
  • Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994;90:844-53
  • Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999;19:1218-22
  • Mazzone A, Epistolato MC, De CR, et al. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol 2004;43:1670-6
  • Mazzone A, Epistolato MC, Gianetti J, et al. Biological features (inflammation and neoangiogenesis) and atherosclerotic risk factors in carotid plaques and calcified aortic valve stenosis: two different sites of the same disease? Am J Clin Pathol 2006;126:494-502
  • Mohty D, Pibarot P, Despres JP, et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008;28:187-93
  • Peltier M, Trojette F, Sarano ME, et al. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol 2003;91:97-9
  • Roberts WC, Ko JM, Hamilton C. Comparison of valve structure, valve weight, and severity of the valve obstruction in 1849 patients having isolated aortic valve replacement for aortic valve stenosis (with or without associated aortic regurgitation) studied at 3 different medical centers in 2 different time periods. Circulation 2005;112:3919-29
  • Aronow WS, Ahn C, Kronzon I. Association of valvular aortic stenosis with symptomatic peripheral arterial disease in older persons. Am J Cardiol 2001;88:1046-7
  • Weisenberg D, Sahar Y, Sahar G, et al. Atherosclerosis of the aorta is common in patients with severe aortic stenosis: an intraoperative transesophageal echocardiographic study. J Thorac Cardiovasc Surg 2005;130:29-32
  • Glader CA, Birgander LS, Soderberg S, et al. Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. Eur Heart J 2003;24:198-208
  • Galante A, Pietroiusti A, Vellini M, et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001;38:1078-82
  • Gerber IL, Stewart RA, Hammett CJ, et al. Effect of aortic valve replacement on c-reactive protein in nonrheumatic aortic stenosis. Am J Cardiol 2003;92:1129-32
  • Allison MA, Cheung P, Criqui MH, et al. Mitral and aortic annular calcification are highly associated with systemic calcified atherosclerosis. Circulation 2006;113:861-6
  • Messika-Zeitoun D, Bielak LF, Peyser PA, et al. Aortic valve calcification: determinants and progression in the population. Arterioscler Thromb Vasc Biol 2007;27:642-8
  • Faggiano P, ntonini-Canterin F, Erlicher A, et al. Progression of aortic valve sclerosis to aortic stenosis. Am J Cardiol 2003;91:99-101
  • Cosmi JE, Kort S, Tunick PA, et al. The risk of the development of aortic stenosis in patients with “benign” aortic valve thickening. Arch Intern Med 2002;162:2345-7
  • Novaro GM, Katz R, Aviles RJ, et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol 2007;50:1992-8
  • Bahler RC, Desser DR, Finkelhor RS, et al. Factors leading to progression of valvular aortic stenosis. Am J Cardiol 1999;84:1044-8
  • Faggiano P, ntonini-Canterin F, Baldessin F, et al. Epidemiology and cardiovascular risk factors of aortic stenosis. Cardiovasc Ultrasound 2006;4:27
  • Koos R, Kuhl HP, Muhlenbruch G, et al. Prevalence and clinical importance of aortic valve calcification detected incidentally on CT scans: comparison with echocardiography. Radiology 2006;241:76-82
  • Koos R, Mahnken AH, Sinha AM, et al. Aortic valve calcification as a marker for aortic stenosis severity: assessment on 16-MDCT. AJR Am J Roentgenol 2004;183:1813-8
  • Morgan-Hughes GJ, Owens PE, Roobottom CA, Marshall AJ. Three dimensional volume quantification of aortic valve calcification using multislice computed tomography. Heart 2003;89:1191-4
  • Sanchez PL, Santos JL, Kaski JC, et al. Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am J Cardiol 2006;97:90-3
  • Kaden JJ, Freyer S, Weisser G, et al. Correlation of degree of aortic valve stenosis by Doppler echocardiogram to quantity of calcium in the valve by electron beam tomography. Am J Cardiol 2002;90:554-7
  • Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611-7
  • Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004;110:1291-5
  • Adler Y, Levinger U, Koren A, et al. Relation of nonobstructive aortic valve calcium to carotid arterial atherosclerosis. Am J Cardiol 2000;86:1102-5
  • Yamaura Y, Nishida T, Watanabe N, et al. Relation of aortic valve sclerosis to carotid artery intima-media thickening in healthy subjects. Am J Cardiol 2004;94:837-9
  • Adler Y, Vaturi M, Herz I, et al. Nonobstructive aortic valve calcification: a window to significant coronary artery disease. Atherosclerosis 2002;161:193-7
  • Yamamoto H, Shavelle D, Takasu J, et al. Valvular and thoracic aortic calcium as a marker of the extent and severity of angiographic coronary artery disease. Am Heart J 2003;146:153-9
  • Wong ND, Sciammarella M, Arad Y, et al. Relation of thoracic aortic and aortic valve calcium to coronary artery calcium and risk assessment. Am J Cardiol 2003;92:951-5
  • Adler Y, Shemesh J, Tenenbaum A, et al. Aortic valve calcium on spiral computed tomography (dual slice mode) is associated with advanced coronary calcium in hypertensive patients. Coron Artery Dis 2002;13:209-13
  • Pohle K, Maffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001;104:1927-32
  • Pohle K, Otte M, Maffert R, et al. Association of cardiovascular risk factors to aortic valve calcification as quantified by electron beam computed tomography. Mayo Clin Proc 2004;79:1242-6
  • Shah SJ, Ristow B, Ali S, et al. Acute myocardial infarction in patients with versus without aortic valve sclerosis and effect of statin therapy (from the Heart and Soul Study). Am J Cardiol 2007;99:1128-33
  • Olsen MH, Wachtell K, Bella JN, et al. Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). Am J Cardiol 2005;95:132-6
  • Wang AY, Wang M, Woo J, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003;14:159-68
  • Aronow WS, Ahn C, Shirani J, Kronzon I. Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis. Am J Cardiol 1999;83:599-600, A8
  • Boon A, Cheriex E, Lodder J, Kessels F. Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart 1997;78:472-4
  • Agmon Y, Khandheria BK, Meissner I, et al. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol 2001;38:827-34
  • Bozbas H, Yildirir A, Atar I, et al. Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification. J Heart Valve Dis 2007;16:387-93
  • Walsh CR, Larson MG, Kupka MJ, et al. Association of aortic valve calcium detected by electron beam computed tomography with echocardiographic aortic valve disease and with calcium deposits in the coronary arteries and thoracic aorta. Am J Cardiol 2004;93:421-5
  • Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001;88:693-5
  • Briand M, Lemieux I, Dumesnil JG, et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006;47:2229-36
  • Bellamy MF, Pellikka PA, Klarich KW, et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002;40:1723-30
  • Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000;101:2497-502
  • Nassimiha D, Aronow WS, Ahn C, Goldman ME. Association of coronary risk factors with progression of valvular aortic stenosis in older persons. Am J Cardiol 2001;87:1313-4
  • Chan KL, Ghani M, Woodend K, Burwash IG. Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. Am J Cardiol 2001;88:690-3
  • Katz R, Wong ND, Kronmal R, et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006;113:2113-9
  • Mohler ER III, Chawla MK, Chang AW, et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 1999;8:254-60
  • Weiss RM, Ohashi M, Miller JD, et al. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 2006;114:2065-9
  • Tanaka K, Sata M, Fukuda D, et al. Age-associated aortic stenosis in apolipoprotein E-deficient mice. J Am Coll Cardiol 2005;46:134-41
  • O'Brien KD, Reichenbach DD, Marcovina SM, et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996;16:523-32
  • Probst V, Le Scouarnec S, Legendre A, et al. Familial aggregation of calcific aortic valve stenosis in the western part of France. Circulation 2006;113:856-60
  • Kolovou G, Daskalova D, Mikhailidis DP. Apolipoprotein E polymorphism and atherosclerosis. Angiology 2003;54:59-71
  • Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007;298:1300-11
  • Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004;141:137-47
  • Kolovou GD, Anagnostopoulou KK, Mikhailidis DP, et al. Association of apolipoprotein E genotype with early onset of coronary heart disease in Greek men. Angiology 2005;56:663-70
  • Kolovou GD, Daskalova DC, Hatzivassiliou M, et al. The epsilon 2 and 4 alleles of apolipoprotein E and ischemic vascular events in the Greek population – implications for the interpretation of similar studies. Angiology 2003;54:51-8
  • Novaro GM, Sachar R, Pearce GL, et al. Association between apolipoprotein E alleles and calcific valvular heart disease. Circulation 2003;108:1804-8
  • Avakian SD, Annicchino-Bizzacchi JM, Grinberg M, et al. Apolipoproteins AI, B, and E polymorphisms in severe aortic valve stenosis. Clin Genet 2001;60:381-4
  • Ortlepp JR, Pillich M, Mevissen V, et al. APOE alleles are not associated with calcific aortic stenosis. Heart 2006;92:1463-6
  • Bella JN, Tang W, Kraja A, et al. Genome-wide linkage mapping for valve calcification susceptibility loci in hypertensive sibships: the Hypertension Genetic Epidemiology Network Study. Hypertension 2007;49:453-60
  • Yilmaz MB, Guray U, Guray Y, et al. Lipid profile of patients with aortic stenosis might be predictive of rate of progression. Am Heart J 2004;147:915-8
  • Gazi IF, Tsimihodimos V, Tselepis AD, et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007;7:53-72
  • Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97
  • Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305
  • Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
  • Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27
  • Efstratiadis G, Tziomalos K, Mikhailidis DP, et al. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008;6:93-107
  • Ribeiro S, Ramos A, Brandao A, et al. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998;13:2037-40
  • Varma R, Aronow WS, McClung JA, et al. Prevalence of valve calcium and association of valve calcium with coronary artery disease, atherosclerotic vascular disease, and all-cause mortality in 137 patients undergoing hemodialysis for chronic renal failure. Am J Cardiol 2005;95:742-3
  • Fox CS, Larson MG, Vasan RS, et al. Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study. J Am Soc Nephrol 2006;17:521-7
  • Ix JH, Shlipak MG, Katz R, et al. Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2007;50:412-20
  • Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115-26
  • Mohler ER III, Gannon F, Reynolds C, et al. Bone formation and inflammation in cardiac valves. Circulation 2001;103:1522-8
  • Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003;107:2181-4
  • O'Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995;92:2163-8
  • Mohler ER III, Adam LP, McClelland P, et al. Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol 1997;17:547-52
  • Srivatsa SS, Harrity PJ, Maercklein PB, et al. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J Clin Invest 1997;99:996-1009
  • Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-610
  • Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65
  • Paraskevas KI, Mikhailidis DP. C-reactive protein (CRP): more than just an innocent bystander? Curr Med Res Opin 2008;24:75-8
  • Skowasch D, Schrempf S, Preusse CJ, et al. Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins. Heart 2006;92:495-8
  • Jeevanantham V, Singh N, Izuora K, et al. Correlation of high sensitivity C-reactive protein and calcific aortic valve disease. Mayo Clin Proc 2007;82:171-4
  • Agmon Y, Khandheria BK, Jamil TA, et al. Inflammation, infection, and aortic valve sclerosis; Insights from the Olmsted County (Minnesota) population. Atherosclerosis 2004;174:337-42
  • Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108:2317-22
  • Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-53
  • Kaden JJ, Kilic R, Sarikoc A, et al. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. Int J Mol Med 2005;16:869-72
  • Kaden JJ, Dempfle CE, Grobholz R, et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 2005;14:80-7
  • Kapadia SR, Yakoob K, Nader S, et al. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 2000;36:208-12
  • Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003;107:2109-14
  • Donger C, Georges JL, Nicaud V, et al. New polymorphisms in the interleukin-10 gene - relationships to myocardial infarction. Eur J Clin Invest 2001;31:9-14
  • Koch W, Kastrati A, Bottiger C, et al. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 2001;159:137-44
  • Lio D, Candore G, Crivello A, et al. Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases and in successful ageing: genetic background of male centenarians is protective against coronary heart disease. J Med Genet 2004;41:790-4
  • Ortlepp JR, Schmitz F, Mevissen V, et al. The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J 2004;25:514-22
  • Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004;24:399-404
  • Jian B, Narula N, Li QY, et al. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 2003;75:457-65
  • Clark-Greuel JN, Connolly JM, Sorichillo E, et al. Transforming growth factor-beta1 mechanisms in aortic valve calcification: increased alkaline phosphatase and related events. Ann Thorac Surg 2007;83:946-53
  • Osman L, Yacoub MH, Latif N, et al. Role of human valve interstitial cells in valve calcification and their response to atorvastatin. Circulation 2006;114:I547-52
  • Koch W, Hoppmann P, Mueller JC, et al. Association of transforming growth factor-beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler Thromb Vasc Biol 2006;26:1114-9
  • Cambien F, Ricard S, Troesch A, et al. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 1996;28:881-7
  • Syrris P, Carter ND, Metcalfe JC, et al. Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. Clin Sci (Lond) 1998;95:659-67
  • Nordstrom P, Glader CA, Dahlen G, et al. Oestrogen receptor alpha gene polymorphism is related to aortic valve sclerosis in postmenopausal women. J Intern Med 2003;254:140-6
  • Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 2000;321:208-13
  • Danesh J, Whincup P, Lewington S, et al. Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur Heart J 2002;23:371-5
  • Juvonen J, Laurila A, Juvonen T, et al. Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1997;29:1054-9
  • Juvonen J, Juvonen T, Laurila A, et al. Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection? Ann Intern Med 1998;128:741-4
  • Nystrom-Rosander C, Thelin S, Hjelm E, et al. High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement. Scand J Infect Dis 1997;29:361-5
  • Folsom AR, Nieto FJ, Sorlie P, et al. Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators. Circulation 1998;98:845-50
  • Haider AW, Wilson PW, Larson MG, et al. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. J Am Coll Cardiol 2002;40:1408-13
  • Singh RK, McMahon AD, Patel H, et al. Prospective analysis of the association of infection with CagA bearing strains of Helicobacter pylori and coronary heart disease. Heart 2002;88:43-6
  • Whincup P, Danesh J, Walker M, et al. Prospective study of potentially virulent strains of Helicobacter pylori and coronary heart disease in middle-aged men. Circulation 2000;101:1647-52
  • Riddle JM, Stein PD, Magilligan DJ Jr, McElroy HH. Evaluation of platelet reactivity in patients with valvular heart disease. J Am Coll Cardiol 1983;1:1381-4
  • Chirkov YY, Mishra K, Chandy S, et al. Loss of anti-aggregatory effects of aortic valve tissue in patients with aortic stenosis. J Heart Valve Dis 2006;15:28-33
  • Stein PD, Sabbah HN, Pitha JV. Continuing disease process of calcific aortic stenosis. Role of microthrombi and turbulent flow. Am J Cardiol 1977;39:159-63
  • Massberg S, Vogt F, Dickfeld T, et al. Activated platelets trigger an inflammatory response and enhance migration of aortic smooth muscle cells. Thromb Res 2003;110:187-94
  • Jagroop IA, Mikhailidis DP. An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets 2000;11:161-5
  • Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
  • Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-809
  • Kakafika AI, Liberopoulos EN, Mikhailidis DP. Fibrinogen: a predictor of vascular disease. Curr Pharm Des 2007;13:1647-59
  • Lowe GD, Danesh J, Lewington S, et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2004;25:252-9
  • Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007;115:2119-27
  • Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007;11:1143-60
  • Shahi CN, Ghaisas NK, Goggins M, et al. Elevated levels of circulating soluble adhesion molecules in patients with nonrheumatic aortic stenosis. Am J Cardiol 1997;79:980-2
  • Poggianti E, Venneri L, Chubuchny V, et al. Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol 2003;41:136-41
  • Bautista LE, Arenas IA, Penuela A, Martinez LX. Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol 2002;55:882-7
  • Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5
  • Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein (a) and stroke. J Clin Pathol 2000;53:487-96
  • Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets 2006;7:761-71
  • Soderberg S, Ahren B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999;246:409-18
  • Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001;104:3052-6
  • Burke AP, Kolodgie FD, Virmani R. Fetuin-A, valve calcification, and diabetes: what do we understand? Circulation 2007;115:2464-7
  • Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-33
  • Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005;67:2295-304
  • Wang AY, Woo J, Lam CW, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005;20:1676-85
  • Fiore CE, Celotta G, Politi GG, et al. Association of high alpha2-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis 2007;195:110-5
  • Ix JH, Chertow GM, Shlipak MG, et al. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007;115:2533-9
  • Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-62
  • Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007;27:15-26
  • Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39
  • Edep ME, Shirani J, Wolf P, Brown DL. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 2000;9:281-6
  • Fondard O, Detaint D, Iung B, et al. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 2005;26:1333-41
  • Satta J, Oiva J, Salo T, et al. Evidence for an altered balance between matrix metalloproteinase-9 and its inhibitors in calcific aortic stenosis. Ann Thorac Surg 2003;76:681-8
  • O'Brien KD. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006;26:1721-8
  • Ortlepp JR, Pillich M, Schmitz F, et al. Lower serum calcium levels are associated with greater calcium hydroxyapatite deposition in native aortic valves of male patients with severe calcific aortic stenosis. J Heart Valve Dis 2006;15:502-8
  • Mills WR, Einstadter D, Finkelhor RS. Relation of calcium-phosphorus product to the severity of aortic stenosis in patients with normal renal function. Am J Cardiol 2004;94:1196-8
  • Drolet MC, Arsenault M, Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol 2003;41:1211-7
  • Linhartova K, Veselka J, Sterbakova G, et al. Parathyroid Hormone and Vitamin D Levels are Independently Associated With Calcific Aortic Stenosis. Circ J 2008;72:245-50
  • Ortlepp JR, Hoffmann R, Ohme F, et al. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 2001;85:635-8
  • Basso C, Boschello M, Perrone C, et al. An echocardiographic survey of primary school children for bicuspid aortic valve. Am J Cardiol 2004;93:661-3
  • Tutar E, Ekici F, Atalay S, Nacar N. The prevalence of bicuspid aortic valve in newborns by echocardiographic screening. Am Heart J 2005;150:513-5
  • Cripe L, Andelfinger G, Martin LJ, et al. Bicuspid aortic valve is heritable. J Am Coll Cardiol 2004;44:138-43
  • Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005;437:270-4
  • Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J Am Coll Cardiol 1997;30:1809-12
  • Lewin MB, Otto CM. The bicuspid aortic valve: adverse outcomes from infancy to old age. Circulation 2005;111:832-4
  • Wallby L, Janerot-Sjoberg B, Steffensen T, Broqvist M. T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 2002;88:348-51
  • Rosenhek R, Baumgartner H. Aortic sclerosis, aortic stenosis and lipid-lowering therapy. Expert Rev Cardiovasc Ther 2008;6:385-90
  • Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002;105:2660-5
  • Wu B, Elmariah S, Kaplan FS, et al. Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease. Arterioscler Thromb Vasc Biol 2005;25:592-7
  • Osman L, Chester AH, Amrani M, et al. A novel role of extracellular nucleotides in valve calcification: a potential target for atorvastatin. Circulation 2006;114:I566-72
  • Novaro GM, Tiong IY, Pearce GL, et al. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001;104:2205-9
  • Shavelle DM, Takasu J, Budoff MJ, et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002;359:1125-6
  • O'Brien KD, Probstfield JL, Caulfield MT, et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005;165:858-62
  • Pai RG, Kapoor N, Bansal RC, Varadarajan P. Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement. Ann Thorac Surg 2006;82:2116-22
  • Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-61
  • Chan KL, Teo K, Tam J, Dumesnil JG. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am Heart J 2007;153:925-31
  • Rossebo AB, Pedersen TR, Allen C, et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007;99:970-3
  • Helske S, Lindstedt KA, Laine M, et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004;44:1859-66
  • O'Brien KD, Shavelle DM, Caulfield MT, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002;106:2224-30
  • Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-97
  • Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol 2007;18:483-91
  • Fielitz J, Hein S, Mitrovic V, et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol 2001;37:1443-9
  • Chambers J. The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors. Heart 2006;92:420-3
  • Kupari M, Turto H, Lommi J. Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? Eur Heart J 2005;26:1790-6
  • Arishiro K, Hoshiga M, Negoro N, et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 2007;49:1482-9
  • Shavelle DM. Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis? Heart 2005;91:1257-9
  • O'Brien KD, Zhao XQ, Shavelle DM, et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med 2004;52:185-91
  • Jimenez-Candil J, Bermejo J, Yotti R, et al. Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study. Heart 2005;91:1311-8
  • Chockalingam A, Venkatesan S, Subramaniam T, et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J 2004;147:E19
  • Olsen MH, Wachtell K, Bella JN, et al. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am J Cardiol 2004;94:1076-80

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.